Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.

被引：0
|
作者：
Armstrong, Andrew J.
Lin, Ping
Higano, Celestia S.
Sternberg, Cora N.
Sonpavde, Guru
Tombal, Bertrand F.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.
    Armstrong, Andrew J.
    Lin, Ping
    Higano, Celestia S.
    Sternberg, Cora N.
    Sonpavde, Guru
    Tombal, Bertrand F.
    Templeton, Arnoud J.
    Fizazi, Karim
    Phung, De
    Wong, Elaine K.
    Krivoshik, Andrew
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Halabi, Susan
    Yang, Qian
    Roy, Akash
    Luo, Bin
    Araujo, John C.
    Logothetis, Christopher
    Sternberg, Cora N.
    Armstrong, Andrew J.
    Carducci, Michael A.
    Chi, Kim N.
    de Bono, Johann S.
    Petrylak, Daniel P.
    Fizazi, Karim
    Higano, Celestia S.
    Morris, Michael J.
    Rathkopf, Dana E.
    Saad, Fred
    Ryan, Charles J.
    Small, Eric J.
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2736 - +
  • [3] Subgroup analysis of Japanese men in the PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC)
    Kimura, G.
    Yonese, J.
    Fukagai, T.
    Kamba, T.
    Nishimura, K.
    Nozawa, M.
    Parli, T.
    Theeuwes, A.
    Beer, T. M.
    Tombal, B.
    Ueda, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 74 - 74
  • [4] Subgroup analysis of Asian men in the PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC)
    Kim, C. -S.
    Choi, Y. D.
    Lee, S. E.
    Lee, H. M.
    Ueda, T.
    Yonese, J.
    Fukagai, T.
    Chiong, E.
    Lau, W.
    Abhyankar, S.
    Theeuwes, A.
    Tombal, B.
    Beer, T. M.
    Kimura, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 73
  • [5] The PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC): subgroup analysis of Asian patients
    Kim, Choung-soo
    Choi, Young Deuk
    Lee, Sangchul
    Lee, Hyun Moo
    Ueda, Takeshi
    Yonese, Junji
    Fukagai, Takashi
    Mansbach, Harry
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Kimura, Go
    BJU INTERNATIONAL, 2015, 116 : 14 - 14
  • [6] External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Halabi, Susan
    Dutta, Sandipan
    Araujo, John C.
    Logothetis, Christopher
    Sternberg, Cora N.
    Armstrong, Andrew J.
    Carducci, Michael Anthony
    Chi, Kim N.
    De Bono, Johann S.
    Petrylak, Daniel Peter
    Fizazi, Karim
    Higano, Celestia S.
    Small, Eric Jay
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Enzalutamide (ENZA) in men with chemotherapy-Naive metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.
    Beer, Tomasz M.
    Armstrong, Andrew J.
    Sternberg, Cora N.
    Higano, Celestia S.
    Rathkopf, Dana E.
    Loriot, Yohann
    Saad, Fred
    Joshua, Anthony M.
    De Bono, Johann Sebastian
    Venner, Peter M.
    Carles, Joan
    Mainwaring, Paul N.
    Evans, Christopher P.
    Parli, Teresa
    Mansbach, Harry H.
    Bhattacharya, Suman
    Van Os, Steve
    Phung, De
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study
    Beer, Tomasz M.
    Armstrong, Andrew J.
    Sternberg, Cora N.
    Higano, Celestia S.
    Iversen, Peter
    Loriot, Yohann
    Rathkopf, Dana E.
    Bhattacharya, Suman
    Carles, Joan
    De Bono, Johann S.
    Evans, Christopher P.
    Joshua, Anthony M.
    Kim, Choung-Soo
    Kimura, Go
    Mainwaring, Paul N.
    Mansbach, Harry H.
    Miller, Kurt
    Noonberg, Sarah B.
    Venner, Peter M.
    Tombal, Bertrand
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] Further analysis of PREVAIL: enzalutamide use in chemotherapy-naive men with metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (06) : 803 - 804
  • [10] Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
    Beer, Tomasz M.
    Armstrong, Andrew J.
    Rathkopf, Dana
    Loriot, Yohann
    Sternberg, Cora N.
    Higano, Celestia S.
    Iversen, Peter
    Evans, Christopher P.
    Kim, Choung-Soo
    Kimura, Go
    Miller, Kurt
    Saad, Fred
    Bjartell, Anders S.
    Borre, Michael
    Mulders, Peter
    Tammela, Teuvo L.
    Parli, Teresa
    Sari, Suha
    van Os, Steve
    Theeuwes, Ad
    Tombal, Bertrand
    EUROPEAN UROLOGY, 2017, 71 (02) : 151 - 154
12345